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Cardiovascular heart diseaseThe b-lactam cholesterol absorption inhibitor ezetimibe is so far the only representative of this class of
compounds on the market today. The goal of this work was to synthesize new amide ezetimibe analogs
from trans-3-amino-(3R,4R)-b-lactam and to test their cytotoxicity and activity as cholesterol absorption
inhibitors. We synthesized six new amide ezetimibe analogs. All new compounds exhibited low toxicity
in MDCKIIwt, hNPC1L1/MDCKII and HepG2 cell lines and showed signiﬁcant inhibition of cholesterol
uptake in hNPC1L1/MDCKII cells. In addition, we determined the activity of the three compounds to
inhibit cholesterol absorption in vivo. Our results demonstrate that these compounds considerably
reduce cholesterol concentrations in liver and small intestine of mice. Thus, our newly synthesized amide
ezetimibe analogs are cholesterol absorption inhibitors in vitro and in vivo.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Coronary heart disease (CHD) is a major health concern and a
leading cause of death in the world1 with high blood cholesterol
concentrations being one of the critical risk factors.2 There are
two major sources of cholesterol in the body: de novo synthesis
in liver and absorption of dietary cholesterol in the small intestine.3
Lowering of blood cholesterol levels can be achieved by blocking
either of the two pathways. De novo synthesis is pharmacologically
inhibited with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (statins),4 whereas absorption of dietary
cholesterol can be blocked with b-lactam cholesterol absorption
inhibitors.5 Ezetimibe 1 (Zetia, Ezetrol) (Fig. 1), FDA approved in
2002, is the only representative of this class of compounds on the
market today. It can be administered as monotherapy or in
combination with statins.6 In 2004, Niemann Pick C1-like1
(NPC1L1) proteinwas identiﬁed as amolecular target of ezetimibe.7The following structural characteristics are important for the
activity of cholesterol absorption inhibitors: the b-lactam back-
bone, aryl group at the N-1 position of the b-lactam, aryl group
optimally substituted with alkoxy or hydroxy group at para-posi-
tion at the C-4 position of the b-lactam, the side chain with three
linking atoms bearing a pendent aryl group at the C-3 position of
the b-lactam, and S conﬁguration at the C-4 chiral center.5
Furthermore, Wang et al. reported that ezetimibe bioisosteres with
an amide group at the 30 position of the C-3 b-lactam side chain
display cholesterol absorption inhibitory activity.8
In this report, we investigated if the introduction of an amide
group at the C-3 position of the b-lactam ring has an effect on
cholesterol absorption inhibitory activity. Furthermore, we wanted
to examine if the incorporation of the cinnamoyl group together
with b-lactam in a single molecule improves its ability to inhibit
cholesterol absorption. Cinnamon, including cinnamaldehyde and
cinnamates as its important constituents, is reported to have anti-
hyperglycemic and anti-hyperlipidemic properties.9–12 Therefore,
we implemented molecular hybridization, a strategy where differ-
ent bioactive entities are combined into a single molecule,13 and
combined two constituents with reported effect on cholesterol
metabolism. In addition, we investigated whether the length of
the side chain containing amide group has a role in the inhibition
of cholesterol absorption. For that reason, either phenyl or benzyl
substituent was attached to the amide group. In continuation of
our research,14–19 we synthesized six new ezetimibe analogs 5a–f
Figure 1. The structure of ezetimibe 1.
Figure 2. Structure of novel amide ezetimibe analogs 5a–f.
Table 1
In vitro cytotoxicity of ezetimibe 1 and newly synthesized amide ezetimibe analogs
5a–fa
Compound MDCKII hNPC1L1/MDCKII HepG2
1 >100 62.29 69.74
5a 66.55 65.06 63.27
5b 63.95 63.27 57.47
5c >100 >100 >100
5d >100 >100 >100
5e 91.23 68.34 67.58
5f 78.64 64.69 71.93
a The results are expressed as LC50 (lM).
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their cytotoxicity, as well as in vitro and in vivo activity.
2. Results and discussion
2.1. Chemistry
2.1.1. Synthesis of novel amide ezetimibe analogs
Enantiomerically pure trans-3-amino-(3R,4R)-b-lactam 2 was
synthesized applying the chiral ester enolate-imine con-
densation.19,20 N-acylation of b-lactam 2 was carried out with the
corresponding acyl chloride 3a–f in dichloromethane in the pres-
ence of Et3N at reﬂux (Scheme 1). OTBDMS protected amides 4a–
fwere obtained in 40–60% yield. Deprotection was performed with
1 M HCl in ethanol to afford 5a–f in 70–90% yield.
2.2. Biological evaluation
2.2.1. Cytotoxicity analysis
Cytotoxicity of ezetimibe 1 and of newly synthesized amides
5a–f was determined using MTT cell proliferation assay inScheme 1. Synthesis of amides 5a–f fromMadine-Darby Canine Kidney II wild-type (MDCKIIwt), MDCKII
cells stably expressing hNPC1L1 (hNPC1L1/MDCKII) and HepG2
cell lines (Table 1). hNPC1L1/MDCKII were used as a pharmacologi-
cally validated model for investigating NPC1L1-mediated choles-
terol uptake.21 LC50 values were determined and values higher
than 100 lM were considered non-toxic. Amides containing cin-
namoyl (5a and b), as well as phenyl group (5e and f) exhibited
low cytotoxicity with LC50 values between 55 and 91 lM and were
comparable to ezetimibe 1 (Table 1). Amides with benzyl sub-
stituent (5c and d) had LC50 values higher than 100 lM. To unam-
biguously conﬁrm that the tested compounds in combination with
micelles do not affect the in vitro cholesterol uptake by a potential
cytotoxic effect, we evaluated their combined cytotoxicity in
MDCKIIwt and hNPC1L1/MDCKII cells. All tested compounds, when
combined with micelles, showed no toxicity (Fig. S1).
2.2.2. In vitro cholesterol uptake
Ezetimibe analogs 5a–f were tested for inhibition of cholesterol
uptake in hNPC1L1/MDCKII cells (Fig. 3). The activity of ezetimibe
1 was determined previously (IC50 = 24 lM, maximum inhibition
of 40% reached at 60 lM concentration).19 Analogs containing a
cinnamoyl group (5a and b) had lowest IC50 values (20 and
18 lM, respectively), with maximum inhibition of 45% which
was reached at 60 lM concentration (Fig. 3A), and their activity
was comparable to ezetimibe 1. Compounds containing a benzyl
substituent (5c and d) exhibited maximum inhibition of40% with
IC50 values of 88 and 46 lM, respectively (Fig. 3B). Derivatives with
a phenyl group (5e and f) inhibited cholesterol uptake by 60–65%
and had IC50 values of 70 and 54 lM, respectively (Fig. 3C). It is
important to notice that derivatives containing 4-F-phenyl at the
side chain displayed lower IC50 values than their phenyl couter-
parts in all three groups (Fig. 3A–C). These results show that amide
ezetimibe analogs 5a–f are potent inhibitors of cholesterol uptake
in vitro.trans-3-amino-(3R,4R)-b-lactam 2.
Figure 3. Inhibition of cholesterol uptake in hNPC1L1/MDCKII cells for compounds (A) 5a (IC50 = 20 lM) and 5b (IC50 = 18 lM), (B) 5c (IC50 = 88 lM) and 5d (IC50 = 46 lM),
(C) 5e (IC50 = 70 lM) and 5f (IC50 = 54 lM). The results are expressed as percentage of inhibition compared to untreated cells and represent mean ± SEM of three independent
experiments. ⁄p <0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.001 determined by one-way ANOVA followed by Dunnett’s test.
Table 2
In vivo inhibition (%) of cholesterol absorption for compounds 1, 5b, 5d, and 5f
Compound Liver Duodenum Jejunum Ileum
1 53 ± 2** 60 ± 6** 52 ± 3* 44 ± 11
5b 49 ± 5** 27 ± 10 35 ± 8 37 ± 15
5d 39 ± 11* 15 ± 12 14 ± 20 24 ± 13
5f 37 ± 8* 42 ± 2 32 ± 6 28 ± 7
3–4 mice per group, 20 mg/kg/day for 2 days mean ± SEM.
* p <0.05.
** p <0.01 determined by one-way ANOVA followed by Dunnett’s test.
T. Drazˇic´ et al. / Bioorg. Med. Chem. 23 (2015) 2353–2359 23552.2.3. In vivo cholesterol absorption
Finally, we tested the in vivo inhibition of cholesterol absorp-
tion of ezetimibe 1 and 4-F-phenyl representatives (5b,d,f) from
each group of ezetimibe analogs. For in vivo testing, we used the
compounds with lower IC50 values and higher inhibition of choles-
terol uptake as determined in vitro. For that purpose, mice were
treated with 20 mg/kg/day of each compound for two days, gav-
aged with [3H]cholesterol and radioactivity was measured in the
liver and three equal parts of the small intestine (duodenum, jeju-
num, ileum). The results are expressed as percent reduction in
radioactivity relative to vehicle (Table 2). All tested compounds
caused a signiﬁcant reduction of radioactivity in the liver.
Cinnamoyl analog 5b decreased [3H]cholesterol content by 49%,
which was comparable to ezetimibe 1 (53%), whereas benzyl (5d)
and phenyl (5f) analogs displayed decreased absorption by 39%
and 37%, respectively. In the three parts of the small intestine (duo-
denum, jejunum, ileum), ezetimibe 1 lowered [3H]cholesterol by
60%, 52%, and 44%, respectively. Our newly sythesized compounds
lowered [3H]cholesterol in all parts of the small intestine in the
range of 14% and 42%, not reaching statistical signiﬁcance in any
part of the intestine. Compound 5b exhibited highest activity with
27%, 35%, and 37% inhibition, respectively. 5d lowered radioactiv-
ity in duodenum and jejunum by 15% and 14%, whereas 5f showed
42% and 32% inhibition, respectively. Decreased cholesterol
absorption in the ileum was comparable between 5d (24%) and
5f (28%). These results suggest that all tested compounds alter
cholesterol metabolism in vivo with 5b showing the highest and
5d resulting in the lowest inhibition of cholesterol absorption.
3. Conclusion
We have successfully synthesized six new amide ezetimibe
analogs 5a–f from trans-3-amino-(3R,4R)-b-lactam. All new com-
pounds exhibit low toxicity and signiﬁcant inhibition of cholesterol
uptake in vitro. Furthermore, inhibitory activity of three newamides (5b,d, and f) was tested in vivo. All three compounds con-
siderably lowered cholesterol level in liver and small intestine,
with the cinnamoyl analog 5b being the most active one and the
benzyl derivative 5d showing fewest effects on cholesterol absorp-
tion. These results suggest that amide ezetimibe analogs are efﬁ-
cient cholesterol absorption inhibitors and that incorporation of
cinnamoyl group as anti-hyperlipidemic moiety contributes to
the inhibitory activity.
4. Experimental section
4.1. General methods
Melting points were determined on a Reichert Thermovar 7905
apparatus and have not been corrected. The IR spectra were
recorded on a PerkinElmer Spectrum RX I FT-IR System spectrome-
ter (KBr pellets technique) (PerkinElmer Instruments, Norwalk, CT,
USA). The NMR spectra were measured in CDCl3 or DMSO-d6 at RT
on a Bruker AV 300 and/or AV 600 spectrometer (Bruker BioSpin
GmbH., Rheinstetten, Germany). d is given in ppm relative to
tetramethylsilane as an internal reference. Optical rotations were
determined on an Optical Activity Automatic Polarimeter AA-10
in 1 dm cell; c in g/100 mL (Optical Activity Ltd, Ramsey,
England). Silica gel column chromatography was performed using
silica gel 70–230 mesh, 60 Å (Sigma–Aldrich, St. Louis, MO, USA
or Acros-Organics, New Jersey, USA) at RT. Samples for HR-MS
analysis were resuspended in 5 lL of THAP/DAC matrix and 1 lL
was spotted onto a MALDI plate. Mass spectra were obtained on
a matrix-assisted laser desorption/ionization-time-of-ﬂight
(MALDI-TOF/TOF) mass spectrometer (4800 Plus MALDI-TOF/TOF
Analyzer, Applied Biosystems, Foster City, CA, USA) equipped with
Nd:YAG laser operating at 355 nm with ﬁring rate 200 Hz in the
positive ion reﬂector mode. 1600 shots per spectrum were taken
covering a mass range of 100–1000 Da, focus mass of 500 Da, and
delay time of 100 ns.
4.2. General procedure for the acylation of 2
The reaction was carried out in dry conditions under argon
atmosphere. To a solution of 2 in anhydrous CH2Cl2 (5 mL), Et3N
(6.0 equiv) and corresponding acyl-chloride (2.0 equiv) were
added. The reaction mixture was reﬂuxed overnight, after which
distilled water was added and the corresponding product extracted
with CH2Cl2 (3  20 mL). Collected organic layers were dried over
Na2SO4 and solvent evaporated to dryness. The product was puri-
ﬁed by silica gel column chromatography (hexane/ethyl acetate
2:1).
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silyloxy)phenyl)-2-oxo-3-azetidinylamino]-3-phenyl-2-propen-
1-one (4a)
Obtained from 2 (63 mg, 0.16 mmol) and (E)-3-phenylprop-2-
enoyl chloride 3a (55 mg, 0.32 mmol) as white solid (43 mg, yield
51%). mp 189–191 C; [a]D20 +106 (c 5 mg/mL EtOAc); FT-IR (KBr)
cm1: 3448, 3236, 3059, 2929, 2856, 1751, 1618, 1509, 1388,
1357, 1259, 1226, 917; 830; 1H NMR (300 MHz, CDCl3): 0.19 (s,
6H, Si–(CH3)2), 0.97 (s, 9H, C–(CH3)3), 4.75 (dd, 1H, J1 = 7.1 Hz,
J2 = 2.2 Hz, C3 b-lactam), 5.05 (d, 1H, J = 2.0 Hz, C4 b-lactam),
6.47 (d, 1H, J = 15.7 Hz, CH@CH–C(@O)–NH), 6.80–6.88 (m, 4H,
Ar-H), 7.17–7.20 (m, 4H, Ar-H), 7.30–7.32 (m, 4H, Ar-H), 7.39–
7.42 (m, 2H, Ar-H, CH@CH–C(@O)–NH), 7.58 (d, 1H, J = 15.7 Hz,
CH@CH–C(@O)–NH); 13C NMR (75 MHz, CDCl3): 4.3 (Si–(CH3)2),
18.3 (C–(CH3)3), 25.7 (C–(CH3)3), 63.3 (C3 b-lactam), 66.4 (C4 b-lac-
tam), 115.9 (d, J = 22.9 Hz, 4-F-C6H4), 119.1 (d, J = 8.1 Hz, 4-F-C6H4),
119.2 (CH@CH–C(@O)–NH), 120.8 (4-OTBDMS-C6H4), 127.6 (4-
OTBDMS-C6H4), 128.1 (C6H5), 128.5 (4-OTBDMS-C6H4), 128.9
(C6H5), 130.1 (C6H5), 133.5 (d, J = 2.8 Hz, 4-F-C6H4), 134.6 (C6H5),
142.7 (CH@CH–C(@O)–NH), 156.3 (4-OTBDMS-C6H4), 159.4 (d,
J = 243.9 Hz, 4-F-C6H4), 165.0 (C@O, b-lactam), 166.5 (C@O);
HRMS for C30H33FN2O3Si (Mr = 516.67852): calcd. m/z [M+Na+]
539.2136, found 539.2148.
4.2.2. (E)-1-[(3R,4R)-1-(4-Fluorophenyl)-4-(4-(t-butyldimethyl-
silyloxy)phenyl)-2-oxo-3-azetidinylamino]-3-(4-ﬂuorophenyl)-
2-propen-1-one (4b)
Obtained from 2 (62 mg, 0.16 mmol) and (E)-3-(-4-ﬂuo-
rophenyl)prop-2-enoyl chloride 3b (59 mg, 0.32 mmol) as white
solid (43 mg, yield 49%). mp 182–184 C; [a]D20 +106 (c 5 mg/mL
EtOAc); FT-IR (KBr) cm1: 3448, 3230, 3039, 2956, 2931, 2858,
1749, 1654, 1611, 1510, 1391, 1358, 1267, 1231, 1158, 914, 830;
1H NMR (300 MHz, CDCl3): 0.19 (s, 6H, Si–(CH3)2), 0.97 (s, 9H, C–
(CH3)3), 4.69 (dd, 1H, J1 = 6.9 Hz, J2 = 2.2 Hz, C3 b-lactam), 5.05 (d,
1H, J = 2.0 Hz, C4 b-lactam), 6.34 (d, 1H, J = 15.6 Hz, CH@CH–
C(@O)–NH), 6.69 (d, 1H, J = 6.8 Hz, CH@CH–C(@O)–NH), 6.83 (d,
2H, J = 8.4 Hz Ar-H), 6.90 (t, 2H, Ar-H, J1,2 = 8.7 Hz), 7.03 (t, 2H,
J1,2 = 8.6 Hz, Ar-H), 7.21–7.26 (m, 4H, Ar-H), 7.40–7.45 (m,2H,
Ar-H), 7.58 (d, 1H, J = 15.6 Hz, CH@CH–C(@O)–NH); 13C NMR
(75 MHz, CDCl3): 4.3 (Si–(CH3)2), 18.3 (C–(CH3)3), 25.7
(C–(CH3)3), 63.2 (C3 b-lactam), 66.4 (C4 b-lactam), 115.9 (d,
J = 22.8 Hz, 4-F-C6H4), 116.0 (d, J = 21.8 Hz, 4-F-C6H4), 118.96
(CH@CH–C(@O)–NH), 119.13 (d, J = 8.0 Hz, 4-F-C6H4), 120.9
(4-OTBDMS-C6H4), 127.6 (4-OTBDMS-C6H4), 128.4 (4-OTBDMS-
C6H4), 130.0 (d, J = 8.2 Hz, 4-F-C6H4), 130.8 (d, J = 3.3 Hz, 4-F-
C6H4), 133.4 (d, J = 2.7 Hz, 4-F-C6H4), 141.4 (CH@CH–C(@O)–NH),
156.4 (4-OTBDMS-C6H4), 159.4 (d, J = 244.6 Hz, 4-F-C6H4), 163.8
(d, J = 250.7 Hz, 4-F-C6H4), 165.3 (C@O, b-lactam), 166.5 (C@O);
HRMS for C30H32F2N2O3Si (Mr = 534.66899): calcd. m/z [M+H+]
535.2223, found 535.2225.
4.2.3. 1-[(3R,4R)-1-(4-Fluorophenyl)-4-(4-(t-butyldimethylsilyl-
oxy)phenyl)-2-oxo-3-azetidinylamino]-2-phenyl-ethan-1-one(4c)
Obtained from 2 (44 mg, 0.11 mmol) and 2-phenylethanoyl
chloride 3c (35 mg, 0.22 mmol) as yellow oil (22 mg, yield 38%).
[a]D20 +10 (c 10 mg/mL EtOAc); FT-IR (KBr) cm1: 3307, 3063,
2956, 2930, 2858, 1761, 1654, 1608, 1510, 1387, 1265, 1228,
1141, 1011, 914, 834; 1H NMR (300 MHz, CDCl3): 0.18 (s, 6H, Si–
(CH3)2), 0.96 (s, 9H, C–(CH3)3), 3.62 (s, 2H, CH2–C(@O)–NH), 4.55
(dd, 1H, J1 = 7.0 Hz, J2 = 2.1 Hz, C3 b-lactam), 4.85 (d, 1H,
J = 2.0 Hz, C4 b-lactam), 6.50 (d, 1H, J = 6.8 Hz, CH2–C(@O)–NH),
6.79–6.88 (m, 4H, Ar-H), 7.13–7.17 (m, 4H, Ar-H), 7.25–7.35 (m,
5H, Ar-H); 13C NMR (75 MHz, CDCl3): 4.3 (Si–(CH3)2), 18.3 (C–
(CH3)3), 25.7 (C–(CH3)3), 43.4 (CH2–C(@O)–NH), 63.3 (C3 b-lactam),
66.3 (C4 b-lactam), 115.9 (d, J = 22.5 Hz, 4-F-C6H4), 119.0 (d,
J = 8.0 Hz, 4-F-C6H4), 120.8 (4-OTBDMS-C6H4), 127.6 (4-OTBDMS-C6H4), 127.7 (C6H5), 128.4 (4-OTBDMS-C6H4), 129.2 (C6H5), 129.6
(C6H5), 133.5 (d, J = 2.6 Hz, 4-F-C6H4), 134.2 (C6H5), 156.3 (4-
OTBDMS-C6H4), 159.4 (d, J = 243.5 Hz, 4-F-C6H4), 164.1 (C@O, b-
lactam), 171.6 (C@O); HRMS for C29H33FN2O3Si (Mr = 504.66782):
calcd. m/z [M+H+] 505.2317, found 505.2309.
4.2.4. 1-[(3R,4R)-1-(4-Fluorophenyl)-4-(4-(t-butyldimethylsilyl-
oxy)phenyl)-2-oxo-3-azetidinylamino]-2-(4-ﬂuorophenyl)-
ethan-1-one (4d)
Obtained from 2 (67 mg, 0.17 mmol) and 2-(4-ﬂuo-
rophenyl)ethanoyl chloride 3d (60 mg, 0.34 mmol) as white solid
(41 mg, yield 45%). mp 66–67 C; [a]D20 +12 (c 10 mg/mL EtOAc);
FT-IR (KBr) cm1: 3310, 2956, 2931, 2858, 1760, 1654, 1608,
1510, 1387, 1265, 1227, 1157, 913, 834; 1H NMR (300 MHz,
CDCl3): 0.18 (s, 6H, Si–(CH3)2), 0.96 (s, 9H, C–(CH3)3), 3.56 (s, 2H,
CH2–C(@O)–NH), 4.60 (dd, 1H, J1 = 7.0 Hz, J2 = 2.0 Hz, C3 b-lactam),
4.83 (d, 1H, J = 2.0 Hz, C4 b-lactam), 6.73 (d, 1H, J = 7.0 Hz, CH2–
C(@O)–NH), 6.79–6.87 (m, 4H, Ar-H), 7.01 (t, 2H, J1,2 = 8.6 Hz, Ar-
H), 7.11–7.16 (m, 4H, Ar-H), 7.21–7.25 (m, 2H, Ar-H); 13C NMR
(75 MHz, CDCl3): 4.3 (Si–(CH3)2), 18.3 (C–(CH3)3), 25.7 (C–
(CH3)3), 42.4 (CH2–C(@O)–NH), 63.4 (C3 b-lactam), 66.2 (C4 b-lac-
tam), 115.9 (d, J = 22.5 Hz, 4-F-C6H4), 116.0 (d, J = 21.4 Hz, 4-F-
C6H4), 119.0 (d, J = 7.9 Hz, 4-F-C6H4), 120.8 (4-OTBDMS-C6H4),
127.5 (4-OTBDMS-C6H4), 128.3 (4-OTBDMS-C6H4), 130.0 (d,
J = 3.3 Hz, 4-F-C6H4), 131.2 (d, J = 8.1 Hz, 4-F-C6H4), 133.4 (d,
J = 2.8 Hz, 4-F-C6H4), 156.4 (4-OTBDMS-C6H4), 159.4 (d,
J = 244.4 Hz, 4-F-C6H4), 162.3 (d, J = 246.1 Hz, 4-F-C6H4), 164.2
(C@O, b-lactam), 171.4 (C@O); HRMS for C29H32F2N2O3Si
(Mr = 522.65829): calcd. m/z [M+H+] 523.2223, found 523.2211.
4.2.5. [(3R,4R)-1-(4-Fluorophenyl)-4-(4-(t-butyldimethylsilyl-
oxy)phenyl)-2-oxo-3-azetidinylamino]phenylformaldehyde (4e)
Obtained from 2 (46 mg, 0.12 mmol) and benzoyl chloride 3e
(33 mg, 0.24 mmol) as white solid (35 mg, yield 60%). mp 80–
82 C; [a]D20 +62 (c 10 mg/mL EtOAc); FT-IR (KBr) cm1: 3339,
2956, 2930, 2857, 1762, 1653, 1510, 1388, 1264, 913, 833; 1H
NMR (300 MHz, CDCl3): 0.20 (s, 6H, Si–(CH3)2), 0.97 (s, 9H, C–
(CH3)3), 4.77 (dd, 1H, J1 = 6.4 Hz, J2 = 2.2 Hz, C3 b-lactam), 5.09 (d,
1H, J = 2.2 Hz, C4 b-lactam), 6.85 (d, 2H, J = 8.6 Hz, Ar-H), 6.90–
6.96 (m, 3H, C(@O)–NH, Ar-H), 7.25–7.30 (m, 4H, Ar-H), 7.42–
7.47 (m, 2H, Ar-H), 7.51–7.56 (m, 1H, Ar-H), 7.80–7.83 (m, 2H,
Ar-H); 13C NMR (150 MHz, CDCl3): 4.2 (Si–(CH3)2), 18.3 (C–
(CH3)3), 25.8 (C–(CH3)3), 63.6 (C3 b-lactam), 66.7 (C4 b-lactam),
116.0 (d, J = 22.8 Hz, 4-F-C6H4), 119.2 (d, J = 8.0 Hz, 4-F-C6H4),
120.9 (4-OTBDMS-C6H4), 127.4 (C6H5), 127.7 (4-OTBDMS-C6H4),
128.5 (4-OTBDMS-C6H4), 128.8 (C6H5), 132.4 (C6H5), 132.9 (C6H5),
133.6 (d, J = 1.8 Hz, 4-F-C6H4), 156.4 (4-OTBDMS-C6H4), 159.5 (d,
J = 244.3 Hz, 4-F-C6H4), 164.4 (C@O, b-lactam), 167.5 (C@O);
HRMS for C28H31FN2O3Si (Mr = 490.64124): calcd. m/z [M+H+]
491.2160, found 491.2161.
4.2.6. [(3R,4R)-1-(4-Fluorophenyl)-4-(4-(t-butyldimethylsilyl-
oxy)phenyl)-2-oxo-3-azetidinylamino](4-ﬂuorophenyl)formal-
dehyde (4f)
Obtained from 2 (46 mg, 0.12 mmol) and 4-ﬂuorbenzoyl chlo-
ride 3f (38 mg, 0.24 mmol) as white solid (25 mg, yield 41%). mp
89–91 C; [a]D20 +57 (c 10 mg/mL EtOAc); FT-IR (KBr) cm1: 3352,
2956, 2931, 2858, 1761, 1653, 1606, 1510, 1472, 1265, 1232,
1157, 914, 834; 1H NMR (300 MHz, CDCl3): 0.20 (s, 6H, Si–
(CH3)2), 0.97 (s, 9H, C–(CH3)3), 4.76 (dd, 1H, J1 = 6.4 Hz,
J2 = 2.2 Hz, C3 b-lactam), 5.07 (d, 1H, J = 2.0 Hz, C4 b-lactam),
6.85 (d, 2H, J = 8.4 Hz, Ar-H), 6.90–6.96 (m, 3H, C(@O)–NH, Ar-H),
7.12 (t, 2H, J1,2 = 8.5 Hz, Ar-H), 7.23–7.29 (m, 4H, Ar-H), 7.80–7.85
(m, 2H, Ar-H); 13C NMR (75 MHz, CDCl3): 4.3 (Si–(CH3)2), 18.3
(C–(CH3)3), 25.8 (C–(CH3)3), 63.5 (C3 b-lactam), 66.6 (C4 b-lactam),
115.92 (d, J = 22.0 Hz, 4-F-C6H4), 115.99 (d, J = 22.8 Hz, 4-F-C6H4),
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OTBDMS-C6H4), 128.3 (4-OTBDMS-C6H4), 129.0 (d, J = 3.2 Hz, 4-F-
C6H4), 129.8 (d, J = 9.1 Hz, 4-F-C6H4), 133.4 (d, J = 2.8 Hz, 4-F-
C6H4), 156.5 (4-OTBDMS-C6H4), 159.5 (d, J = 244.1 Hz, 4-F-C6H4),
164.5 (C@O, b-lactam), 165.3 (d, J = 253.5 Hz, 4-F-C6H4), 166.4
(C@O); HRMS for C28H30F2N2O3Si (Mr = 508.63171): calcd. m/z
[M+H+] 509.2066, found 509.2060.
4.3. General procedure for the preparation of compounds 5a–f
To a solution of 4a–f (35 mM) in ethanol, 1 M HCl (5.5 equiv)
was added and the mixture was stirred at room temperature over-
night. After the completion of the reaction, distilled water (10 mL)
was added to the reaction mixture and the resulting mixture was
extracted with ethyl acetate (3  20 mL). Organic layers were col-
lected, dried over Na2SO4 and the solvent was evaporated. The pro-
duct was puriﬁed by silica gel column chromatography (hexane/
ethyl acetate 1:1).
4.3.1. (E)-N-((2R,3R)-1-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-
4-oxoazetidin-3-yl)cinnamamide (5a)
Obtained from 4a (87 mg, 0.17 mmol) as white crystals (55 mg,
yield 80%). mp 123–125 C; [a]D20 +64 (c 5 mg/mL EtOAc); FT-IR
(KBr) cm1: 3283, 3059, 1740, 1656, 1615, 1509, 1388, 1348,
1224, 975, 832; 1H NMR (300 MHz, DMSO-d6): 4.72 (dd, 1H,
J1 = 7.9 Hz, J2 = 2.4 Hz, C3 b-lactam), 5.07 (d, 1H, J = 2.4 Hz, C4 b-
lactam), 6.63 (d, 1H, J = 15.8 Hz, CH@CH–C(@O)–NH), 6.76 (d, 2H,
J = 8.3 Hz, Ar-H), 7.16 (t, 2H, J1,2 = 8.8 Hz, Ar-H), 7.23–7.29 (m, 4H,
Ar-H), 7.39–7.50 (m, 4H, CH@CH–C(@O)–NH, Ar-H), 7.57–7.60
(m, 2H, Ar-H), 8.98 (d, 1H, J = 7.9 Hz, CH@CH–C(@O)–NH), 9.55 (s,
1H, Ar-OH); 13C NMR (150 MHz, DMSO-d6): 61.8 (C3 b-lactam),
65.6 (C4 b-lactam), 115.7 (4-OH-C6H4), 115.9 (d, J = 22.4 Hz, 4-F-
C6H4), 118.7 (d, J = 7.9 Hz, 4-F-C6H4), 120.8 (CH@CH–C(@O)–NH),
126.6 (4-OH-C6H4), 127.7 (4-OH-C6H4), 128.0 (C6H5), 129.0
(C6H5), 129.8 (C6H5), 133.8 (4-F-C6H4), 134.5 (C6H5), 140.3
(CH@CH–C(@O)–NH), 157.7 (C@O), 158.2 (d, J = 240.7 Hz, 4-F-
C6H4), 164.7 (4-OH-C6H4), 165.2 (C@O, b-lactam); HRMS for
C24H19FN2O3 (Mr = 402.41766): calcd. m/z [M+H+] 403.1452, found
403.1457.
4.3.2. (E)-3-(4-Fluorophenyl)-N-((2R,3R)-1-(4-ﬂuorophenyl)-2-
(4-hydroxyphenyl)-4-oxoazetidin-3-yl)acrylamide (5b)
Obtained from 4b (74 mg, 0.14 mmol) as white crystals (53 mg,
yield 92%). mp 117–119 C; [a]D20 +61 (c 5 mg/mL EtOAc); FT-IR
(KBr) cm1: 3309, 1740, 1661, 1599, 1508, 1388, 1349, 1226,
1157, 976, 829; 1H NMR (300 MHz, DMSO-d6): 4.72 (dd, 1H,
J1 = 8.1 Hz, J2 = 2.4 Hz, C3 b-lactam), 5.06 (d, 1H, J = 2.3 Hz, C4 b-
lactam), 6.58 (d, 1H, J = 16.0 Hz, CH@CH–C(@O)–NH), 6.76 (d, 2H,
J = 8.3 Hz, Ar-H), 7.16 (t, 2H, J1,2 = 8.8 Hz, Ar-H), 7.22–7.29 (m, 6H,
Ar-H), 7.47 (d, 1H, J = 16.0 Hz, CH@CH–C(@O)–NH), 7.63–7.68 (m,
2H, Ar-H), 8.96 (d, 1H, J = 7.9 Hz, CH@CH–C(@O)–NH), 9.55 (s, 1H,
Ar-OH); 13C NMR (75 MHz, DMSO-d6): 61.8 (C3 b-lactam), 65.6
(C4 b-lactam), 115.8 (4-OH-C6H4), 115.92 (d, J = 22.7 Hz, 4-F-
C6H4), 115.97 (d, J = 21.7 Hz, 4-F-C6H4), 118.7 (d, J = 8.1 Hz, 4-F-
C6H4), 120.7 (CH@CH–C(@O)–NH), 126.6 (4-OH-C6H4), 128.0 (4-
OH-C6H4), 130.0 (d, J = 8.1 Hz, 4-F-C6H4), 131.2 (d, J = 3.1 Hz, 4-F-
C6H4), 133.8 (d, J = 2.3 Hz, 4-F-C6H4), 139.2 (CH@CH–C(@O)–NH),
157.7 (C@O), 158.3 (d, J = 241.0 Hz, 4-F-C6H4), 162.9 (d,
J = 248.1 Hz, 4-F-C6H4), 164.7 (4-OH-C6H4), 165.1 (C@O, b-lactam);
HRMS for C24H18F2N2O3 (Mr = 420.40813): calcd. m/z [M+H+]
421.1358, found 421.1360.
4.3.3. N-((2R,3R)-1-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-4-
oxoazetidin-3-yl)-2-phenylacetamide (5c)
Obtained from 4c (40 mg, 0.08 mmol) as white crystals (27 mg,
yield 88%). mp 185–187 C; [a]D20 +15 (c 10 mg/mL EtOAc); FT-IR(KBr) cm1: 3356, 3026, 1755, 1654, 1509, 1387, 1273, 1229,
1146, 832; 1H NMR (300 MHz, DMSO-d6): 3.50 (s, 2H, CH2–
C(@O)–NH), 4.59 (dd, 1H, J1 = 7.6 Hz, J2 = 2.2 Hz, C3 b-lactam),
4.97 (d, 1H, J = 2.0 Hz, C4 b-lactam), 6.74 (d, 2H, J = 8.5 Hz, Ar-H),
7.13 (t, 2H, J1,2 = 8.7 Hz, Ar-H), 7.20–7.33 (m, 9H, Ar-H), 8.87 (d,
1H, CH2–C(@O)–NH, J = 7.9 Hz), 9.53 (s, 1H, Ar-OH); 13C NMR
(75 MHz, DMSO-d6): 41.9 (CH2–C(@O)–NH), 61.6 (C3 b-lactam),
65.4 (C4 b-lactam), 115.9 (d, J = 22.8 Hz, 4-F-C6H4), 115.7 (4-OH-
C6H4), 118.6 (d, J = 7.8 Hz, 4-F-C6H4), 126.5 (4-OH-C6H4), 126.6
(C6H5), 128.0 (4-OH-C6H4), 128.3 (C6H5), 129.1 (C6H5), 133.8 (d,
J = 2.5 Hz, 4-F-C6H4), 135.6 (C6H5), 157.7 (C@O), 158.2 (d,
J = 242.4 Hz, 4-F-C6H4), 164.7 (4-OH-C6H4), 170.6 (C@O, b-lactam);
HRMS for C23H19FN2O3 (Mr = 390.40696): calcd. m/z [M+H+]
391.1452, found 391.1442.
4.3.4. 2-(4-Fluorophenyl)-N-((2R,3R)-1-(4-ﬂuorophenyl)-2-(4-
hydroxyphenyl)-4-oxoazetidin-3-yl)acetamide (5d)
Obtained from 4d (77 mg, 0.15 mmol) as white crystals (51 mg,
yield 84%). mp 103–105 C; [a]D20 +14 (c 10 mg/mL EtOAc); FT-IR
(KBr) cm1: 3274, 1750, 1683, 1509, 1388, 1348, 1220, 1146,
984, 831; 1H NMR (300 MHz, DMSO-d6): 3.51 (s, 2H, CH2–C(@O)–
NH), 4.58 (dd, 1H, J1 = 7.9 Hz, J2 = 2.5 Hz, C3 b-lactam), 4.97 (d,
1H, J = 2.4 Hz, C4 b-lactam), 6.74 (d, 2H, J = 8.6 Hz, Ar-H), 7.10–
7.31 (m, 10H, Ar-H), 8.87 (d, 1H, J = 8.0 Hz, CH2–C(@O)–NH), 9.55
(s, 1H, Ar-OH); 13C NMR (75 MHz, DMSO-d6): 40.9 (CH2–C(@O)–
NH), 61.6 (C3 b-lactam), 65.4 (C4 b-lactam), 115.0 (d, J = 20.8 Hz,
4-F-C6H4), 115.7 (4-OH-C6H4), 115.9 (d, J = 22.7 Hz, 4-F-C6H4),
118.7 (d, J = 8.2 Hz, 4-F-C6H4), 126.6 (4-OH-C6H4), 128.0 (4-OH-
C6H4), 131.0 (d, J = 7.8 Hz, 4-F-C6H4), 131.7 (d, J = 3.4 Hz, 4-F-
C6H4), 133.8 (d, J = 1.9 Hz, 4-F-C6H4), 157.7 (C@O), 158.2 (d,
J = 240.5 Hz, 4-F-C6H4), 161.1 (d, J = 242.6 Hz, 4-F-C6H4), 164.7 (4-
OH-C6H4), 170.6 (C@O, b-lactam); HRMS for C23H18F2N2O3
(Mr = 408.39743): calcd. m/z [M+H+] 409.1358, found 409.1357.
4.3.5. N-((2R,3R)-1-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-4-
oxoazetidin-3-yl)benzamide (5e)
Obtained from 4e (62 mg, 0.13 mmol) as white crystals (35 mg,
yield 74%). mp 226–228 C; [a]D20 +69 (c 10 mg/mL EtOAc); FT-IR
(KBr) cm1: 3294, 1741, 1635, 1508, 1396, 1225, 1170, 828; 1H
NMR (300 MHz, DMSO-d6): 4.78 (dd, 1H, J1 = 8.0 Hz, J2 = 2.6 Hz,
C3 b-lactam), 5.14 (d, 1H, J = 2.5 Hz, C4 b-lactam), 6.77 (d, 2H,
J = 8.7 Hz, Ar-H), 7.17 (t, 2H, J1,2 = 8.9 Hz, Ar-H), 7.25–7.32 (m, 4H,
Ar-H), 7.48–7.60 (m, 3H, Ar-H), 7.86–7.89 (m, 2H, Ar-H), 9.31 (d,
1H, J = 8.1 Hz, C(@O)–NH), 9.54 (s, 1H, Ar-OH); 13C NMR (75 MHz,
DMSO-d6): 61.5 (C3 b-lactam), 65.8 (C4 b-lactam), 115.8 (4-OH-
C6H4), 115.9 (d, J = 22.7 Hz, 4-F-C6H4), 118.6 (d, J = 8.2 Hz, 4-F-
C6H4), 126.7 (4-OH-C6H4), 127.3 (4-OH-C6H4), 128.1 (C6H5), 128.6
(C6H5), 131.9 (C6H5), 133.0 (C6H5), 133.9 (d, J = 2.1 Hz, 4-F-C6H4),
157.7 (C@O), 158.2 (d, J = 240.4 Hz, 4-F-C6H4), 164.8 (4-OH-C6H4),
166.1 (C@O, b-lactam); HRMS for C22H17FN2O3 (Mr = 376.38038):
calcd. m/z [M+H+] 377.1296, found 377.1291.
4.3.6. 4-Fluoro-N-((2R,3R)-1-(4-ﬂuorophenyl)-2-(4-hydroxyph-
enyl)-4-oxoazetidin-3-yl)benzamide (5f)
Obtained from 4f (81 mg, 0.16 mmol) as white crystals (45 mg,
yield 71%). mp 235–237 C; [a]D20 +63 (c 10 mg/mL EtOAc); FT-IR
(KBr) cm1: 3295, 1743, 1635, 1602, 1508, 1457, 1395, 1232,
1153, 828; 1H NMR (300 MHz, DMSO-d6): 4.77 (d, 1H, J = 7.9 Hz,
C3 b-lactam), 5.12 (d, 1H, J = 2.4 Hz, C4 b-lactam), 6.77 (d, 2H,
J = 7.7 Hz, Ar-H), 7.17 (t, 2H, J1,2 = 8.2 Hz, Ar-H), 7.24–7.37 (m, 6H,
Ar-H), 7.92–7.97 (m, 2H, Ar-H), 9.33 (d, 1H, J = 7.7 Hz, C(@O)–
NH), 9.54 (s, 1H, Ar-OH); 13C NMR (75 MHz, DMSO-d6): 61.5 (C3
b-lactam), 65.8 (C4 b-lactam), 115.6 (d, J = 21.7 Hz, 4-F-C6H4),
115.8 (4-OH-C6H4),116.0 (d, J = 22.6 Hz, 4-F-C6H4), 118.6 (d,
J = 7.8 Hz, 4-F-C6H4), 126.7 (4-OH-C6H4), 128.1 (4-OH-C6H4),
129.5 (d, J = 2.8 Hz, 4-F-C6H4), 130.1 (d, J = 8.9 Hz, 4-F-C6H4),
2358 T. Drazˇic´ et al. / Bioorg. Med. Chem. 23 (2015) 2353–2359133.9 (d, J = 2.5 Hz, 4-F-C6H4), 157.7 (C@O), 158.2 (d, J = 242.6 Hz,
4-F-C6H4), 164.3 (d, J = 251.8 Hz, 4-F-C6H4), 164.7 (4-OH-C6H4),
165.1 (C@O, b-lactam); HRMS for C22H16F2N2O3 (Mr = 394.37085):
calcd. m/z [M+H+] 395.1202, found 395.1195.
4.4. Cell culture and stable transfection with human NPC1L1
protein
Madin-Darby Canine Kidney II wild type (MDCKIIwt), MDCKII
cells stably expressing human NPC1L1 (hNPC1L1/MDCKII), and
HepG2 cells were cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) (Gibco, Life Technologies, Carlsbad, USA) containing 10%
fetal calf serum (FCS) (Sigma–Aldrich, Munich, Germany), 1% peni-
cillin/streptomycin in a humidiﬁed 5% CO2 incubator at 37 C.
MDCKIIwt cells were stably transfected with human NPC1L1 using
Lipofectamine LTX (Life Technologies, Carlsbad, USA) according to
the manufacturer’s protocol. After 48 h, selection with 1000 lg/
mL G418 (Sigma–Aldrich, Munich, Germany) was started.
Selection lasted for two weeks, after which transfected cells were
maintained in the medium containing 500 lg/mL G418.
4.5. Cytotoxicity determination
MDCKIIwt, hNPC1L1/MDCKII, and HepG2 cells were plated in
96-well microtiter plates at 2  104 cells/mL on day 0. On the next
day, tested compounds were added to obtain ﬁve 10-fold consecu-
tive dilutions in range from 108 to 104 mol/L, and incubated for
further 72 h. Cytotoxicity of the compounds was determined by
the MTT cell proliferation assay (Sigma–Aldrich, Munich,
Germany).22 The results are expressed as LC50 values. The absor-
bance (A) was measured on a microplate reader at 570 nm.
Cytotoxicity of each compound was tested in quadruplicate in
three independent experiments. Furthermore, toxicity of the com-
pounds in combination with micelles was tested using the same
method. MDCKIIwt and hNPC1L1/MDCKII were plated in 96-well
microtiter plates (150 lL medium/well) at 2  105 cells/mL 24 h
before the experiment. Micelles were prepared according to the
modiﬁed method described by Field et al.23 In brief, micellar com-
ponents were mixed with DMEM supplemented with 10% FCS to
obtain ﬁnal concentrations of 0.25 mM oleic acid, 50 lM choles-
terol, 10 lM compactin, 50 lMmevalonate, 5 mM Na-taurocholate
(Sigma–Aldrich, Munich, Germany) and sonicated. Tested com-
pounds (25, 50, 100, 150, 200 lM) were added to the prepared
medium, vortexed and applied to the cells for 1 h. Cytotoxicity
was determined using the MTT assay.
4.6. In vitro cholesterol uptake
In vitro cholesterol uptake was determined as described by
Drazˇic´ et al.19 In brief, hNPC1L1/MDCKII cells were plated in 24-
well plates at 5  105 cells/mL medium (500 lL medium/well) in
DMEM supplemented with 5% LPDS 24 h before the treatment.
Cells were washed once with PBS and medium containing micelles,
[3H]cholesterol (0.18 lCi/mL medium) ([1,2-3H(N)] cholesterol,
1 mCi/mL, ARC Inc., St. Louis, USA) and tested compounds in con-
centrations of 0–200 lM was added. After 1 h, the medium was
removed, cells were washed three times with ice-cold 0.2% free
fatty acid-free BSA and lysed. Radioactivity in the lysate (100 lL)
was measured by liquid scintillation counting. Protein content in
lysates was determined with the DC Protein Assay (Bio-Rad,
Hercules, USA). The results were expressed as percentage of inhibi-
tion compared to untreated cells in CPM/mg protein. Activity of
each compound was tested in duplicate in three independent
experiments.4.7. In vivo acute cholesterol absorption
26 weeks old male C57BL/6 mice (3–4 per group) were main-
tained in a temperature-controlled environment under a 12 h
light/12 h dark cycle with free access to chow diet (Altromin
Spezialfutter GmbH, Lage, Germany) and water. For two days, mice
were treated with ezetimibe, tested compounds (20 mg/kg/day) or
vehicle. For the treatment, compounds were dissolved in corn oil
and administered to mice (100 lL) after 4 h fasting by oral gavage.
On day 2, 90 min after compound administration, mice were gav-
aged with corn oil (200 lL) containing [3H]cholesterol (2 lCi)
([1,2-3H(N)] cholesterol, 1 mCi/mL, ARC Inc., St. Louis, USA). Liver
and small intestines were collected 4 h post-gavage and choles-
terol uptake and absorption were determined as previously
described.24 Animal experiments were performed according to
the standards set by the Austrian Federal Ministry of Science,
Research, and Economy, Vienna, Austria.
4.8. Statistical analysis
The results are presented as mean ± SEM Statistical analysis was
performed using one-way analysis of variance (ANOVA) followed
by Dunnett’s test for multiple comparisons using (GraphPad
Prism 5.0, San Diego, USA). Differences were considered signiﬁcant
at p <0.05.
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